vs
Side-by-side financial comparison of GoodRx Holdings, Inc. (GDRX) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.
GoodRx Holdings, Inc. is the larger business by last-quarter revenue ($194.8M vs $127.1M, roughly 1.5× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -1.9%). GoodRx Holdings, Inc. produced more free cash flow last quarter ($31.6M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -0.8%).
GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.
Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.
GDRX vs ZLAB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $194.8M | $127.1M |
| Net Profit | $5.4M | — |
| Gross Margin | — | 51.0% |
| Operating Margin | 11.6% | -54.6% |
| Net Margin | 2.8% | — |
| Revenue YoY | -1.9% | 17.1% |
| Net Profit YoY | -19.5% | — |
| EPS (diluted) | $0.02 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $194.8M | $127.1M | ||
| Q3 25 | $196.0M | $115.4M | ||
| Q2 25 | $203.1M | $109.1M | ||
| Q1 25 | $203.0M | $105.7M | ||
| Q4 24 | $198.6M | $108.5M | ||
| Q3 24 | $195.3M | $101.8M | ||
| Q2 24 | $200.6M | $100.1M | ||
| Q1 24 | $197.9M | $87.1M |
| Q4 25 | $5.4M | — | ||
| Q3 25 | $1.1M | $-36.0M | ||
| Q2 25 | $12.8M | $-40.7M | ||
| Q1 25 | $11.1M | $-48.4M | ||
| Q4 24 | $6.7M | — | ||
| Q3 24 | $4.0M | $-41.7M | ||
| Q2 24 | $6.7M | $-80.3M | ||
| Q1 24 | $-1.0M | $-53.5M |
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
| Q4 25 | 11.6% | -54.6% | ||
| Q3 25 | 7.5% | -42.3% | ||
| Q2 25 | 13.2% | -50.3% | ||
| Q1 25 | 11.5% | -53.3% | ||
| Q4 24 | 9.2% | -62.6% | ||
| Q3 24 | 10.5% | -66.6% | ||
| Q2 24 | 9.9% | -76.0% | ||
| Q1 24 | 3.7% | -80.7% |
| Q4 25 | 2.8% | — | ||
| Q3 25 | 0.6% | -31.2% | ||
| Q2 25 | 6.3% | -37.3% | ||
| Q1 25 | 5.4% | -45.8% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 2.0% | -40.9% | ||
| Q2 24 | 3.3% | -80.2% | ||
| Q1 24 | -0.5% | -61.4% |
| Q4 25 | $0.02 | $-0.05 | ||
| Q3 25 | $0.00 | $-0.03 | ||
| Q2 25 | $0.04 | $-0.04 | ||
| Q1 25 | $0.03 | $-0.04 | ||
| Q4 24 | $0.01 | $-0.09 | ||
| Q3 24 | $0.01 | $-0.04 | ||
| Q2 24 | $0.02 | $-0.08 | ||
| Q1 24 | $0.00 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $261.8M | $689.6M |
| Total DebtLower is stronger | $495.0M | — |
| Stockholders' EquityBook value | $616.3M | $715.5M |
| Total Assets | $1.4B | $1.2B |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $261.8M | $689.6M | ||
| Q3 25 | $273.5M | $717.2M | ||
| Q2 25 | $281.3M | $732.2M | ||
| Q1 25 | $301.0M | $757.3M | ||
| Q4 24 | $448.3M | $779.7M | ||
| Q3 24 | $423.8M | $616.1M | ||
| Q2 24 | $524.9M | $630.0M | ||
| Q1 24 | $533.3M | $650.8M |
| Q4 25 | $495.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $500.0M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $616.3M | $715.5M | ||
| Q3 25 | $600.7M | $759.9M | ||
| Q2 25 | $643.0M | $791.7M | ||
| Q1 25 | $654.3M | $810.8M | ||
| Q4 24 | $724.7M | $840.9M | ||
| Q3 24 | $696.4M | $667.7M | ||
| Q2 24 | $669.4M | $704.2M | ||
| Q1 24 | $631.1M | $762.2M |
| Q4 25 | $1.4B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.4B | $985.3M | ||
| Q2 24 | $1.5B | $987.4M | ||
| Q1 24 | $1.5B | $988.4M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.69× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-26.0M |
| Free Cash FlowOCF − Capex | $31.6M | $-26.7M |
| FCF MarginFCF / Revenue | 16.2% | -21.0% |
| Capex IntensityCapex / Revenue | 0.6% | 0.5% |
| Cash ConversionOCF / Net Profit | 6.06× | — |
| TTM Free Cash FlowTrailing 4 quarters | $164.4M | $-158.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-26.0M | ||
| Q3 25 | $76.0M | $-32.0M | ||
| Q2 25 | $49.6M | $-31.0M | ||
| Q1 25 | $9.4M | $-61.7M | ||
| Q4 24 | $44.7M | $-55.8M | ||
| Q3 24 | $86.9M | $-26.8M | ||
| Q2 24 | $9.7M | $-42.2M | ||
| Q1 24 | $42.6M | $-90.1M |
| Q4 25 | $31.6M | $-26.7M | ||
| Q3 25 | $74.3M | $-35.0M | ||
| Q2 25 | $49.2M | $-33.9M | ||
| Q1 25 | $9.3M | $-63.2M | ||
| Q4 24 | $44.6M | $-58.4M | ||
| Q3 24 | $86.5M | $-28.2M | ||
| Q2 24 | $9.4M | $-42.9M | ||
| Q1 24 | $42.2M | $-91.1M |
| Q4 25 | 16.2% | -21.0% | ||
| Q3 25 | 37.9% | -30.4% | ||
| Q2 25 | 24.2% | -31.1% | ||
| Q1 25 | 4.6% | -59.9% | ||
| Q4 24 | 22.4% | -53.8% | ||
| Q3 24 | 44.3% | -27.7% | ||
| Q2 24 | 4.7% | -42.9% | ||
| Q1 24 | 21.3% | -104.5% |
| Q4 25 | 0.6% | 0.5% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.1% | 2.4% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
| Q4 25 | 6.06× | — | ||
| Q3 25 | 67.94× | — | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 6.64× | — | ||
| Q3 24 | 21.91× | — | ||
| Q2 24 | 1.45× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
